| |
| |
|
| Insider
Information: |
Maier Paul V |
| Relationship: |
Director |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
286,477 |
|
|
Indirect Shares
|
11,360 |
|
|
| Direct
Value |
$7,294,418 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
297,837 |
|
|
| Total
Value |
$7,294,418 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Ligand Pharmaceuticals Inc |
LGND |
Sr. V-P, CFO |
2006-11-20 |
84,951 |
2006-11-16 |
0 |
Premium* |
|
|
International Stem Cell Corp |
ISCO |
Director |
2019-04-18 |
31,710 |
2015-12-31 |
1,360 |
Premium* |
|
|
Talon Therapeutics Inc |
TLON |
Director |
2013-07-17 |
0 |
2008-06-18 |
0 |
Premium* |
|
|
Pure Bioscience |
PURE |
Director |
2012-07-31 |
69,110 |
2009-05-14 |
0 |
Premium* |
|
|
Sequenom Inc |
SQNM |
Chief Financial Officer |
2014-02-10 |
63,789 |
2014-02-10 |
10,000 |
Premium* |
|
|
Mabvax Therapeutics Holdings Inc |
MBVX |
|
2018-04-02 |
23,063 |
2015-05-29 |
0 |
Premium* |
|
|
Seelos Therapeutics Inc |
SEEL |
Director |
2017-01-05 |
13,854 |
2016-04-05 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
97 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| LGND |
Ligand Pharmaceuticals In... |
Sr. V-P, CFO |
• – – |
2003-11-21 |
4 |
OE |
$9.10 |
$14,951 |
D/D |
1,643 |
56,453 |
|
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Sr. V-P, CFO |
• – – |
2004-03-22 |
4 |
OE |
$10.06 |
$17,569 |
D/D |
1,747 |
58,539 |
|
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Sr. V-P, CFO |
• – – |
2004-03-26 |
4 |
OE |
$11.26 |
$44,331 |
D/D |
3,937 |
62,476 |
|
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Sr. V-P, CFO |
• – – |
2004-05-17 |
4 |
AS |
$17.43 |
$69,720 |
D/D |
(4,000) |
58,929 |
|
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Sr. V-P, CFO |
• – – |
2004-05-26 |
4 |
AS |
$19.50 |
$39,000 |
D/D |
(2,000) |
56,929 |
|
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Sr. V-P, CFO |
• – – |
2004-06-01 |
4 |
AS |
$20.35 |
$122,160 |
D/D |
(6,000) |
50,929 |
|
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Sr. V-P, CFO |
• – – |
2004-07-01 |
4 |
AS |
$17.00 |
$68,125 |
D/D |
(4,000) |
47,365 |
|
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Sr. V-P, CFO |
• – – |
2004-08-05 |
4 |
OE |
$5.50 |
$31,350 |
D/D |
5,700 |
53,065 |
|
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Sr. V-P, CFO |
• – – |
2004-09-08 |
4 |
OE |
$8.65 |
$324,553 |
D/D |
36,245 |
89,310 |
|
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Sr. V-P, CFO |
• – – |
2006-11-16 |
4 |
S |
$11.35 |
$98,112 |
I/I |
(8,595) |
0 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Sr. V-P, CFO |
• – – |
2006-11-16 |
4 |
S |
$11.25 |
$168,048 |
D/D |
(14,921) |
84,951 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Sr. V-P, CFO |
• – – |
2006-11-16 |
4 |
OE |
$9.31 |
$138,952 |
D/D |
14,921 |
85,051 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Sr. V-P, CFO |
• – – |
2006-11-16 |
4 |
S |
$11.30 |
$355,441 |
D/D |
(31,256) |
84,951 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Sr. V-P, CFO |
• – – |
2006-11-16 |
4 |
OE |
$9.31 |
$233,548 |
D/D |
25,079 |
89,502 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Sr. V-P, CFO |
• – – |
2006-11-17 |
4 |
OE |
$9.25 |
$607,770 |
D/D |
65,523 |
120,185 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Sr. V-P, CFO |
• – – |
2006-11-17 |
4 |
S |
$11.28 |
$437,437 |
D/D |
(38,148) |
112,326 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Sr. V-P, CFO |
• – – |
2006-11-17 |
4 |
OE |
$7.25 |
$84,586 |
D/D |
11,667 |
88,498 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Sr. V-P, CFO |
• – – |
2006-11-17 |
4 |
S |
$11.25 |
$443,295 |
D/D |
(39,042) |
84,951 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Sr. V-P, CFO |
• – – |
2006-11-20 |
4 |
S |
$11.36 |
$308,704 |
D/D |
(27,016) |
84,951 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Sr. V-P, CFO |
• – – |
2006-11-20 |
4 |
OE |
$9.25 |
$249,898 |
D/D |
27,016 |
105,267 |
0 |
- |
|
| ISCO |
International Stem Cell C... |
Director |
– • – |
2007-07-20 |
4 |
B |
$1.70 |
$3,400 |
D/D |
2,000 |
2,000 |
2.31 |
- |
|
| TLON |
Talon Therapeutics Inc |
Director |
– • – |
2008-06-18 |
4 |
B |
$0.75 |
$5,250 |
D/D |
7,000 |
7,000 |
2.39 |
- |
|
| ISCO |
International Stem Cell C... |
Director |
– • – |
2008-12-29 |
4 |
A |
$0.00 |
$0 |
I/I |
280,000 |
282,000 |
0 |
- |
|
| PURE |
Pure Bioscience |
Director |
– • – |
2009-05-14 |
4 |
A |
$2.34 |
$50,778 |
D/D |
21,700 |
21,700 |
0 |
- |
|
| SQNM |
Sequenom Inc |
Chief Financial Officer |
• – – |
2010-01-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,250 |
6,250 |
0 |
- |
|
97 Records found
|
|
Page 1 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
